Notably, the amplification of MYCN is found in 20% of high-risk NB patients and amplification of MYCN is considered the best genetic marker and therapeutic target for high-risk NB (Weiss et al., 1997; Valentijn et al., 2012). Here, MYCN is linked to neuroblastoma.